Glenmark Pharmaceuticals has informed that it enclosed a media release on January 14,2021 titled ‘Glenmark Specialty S.A. (Switzerland) receives NDA Approval by the United States Food and Drug Administration (FDA) for Ryaltris™ Nasal Spray for the Treatment of Symptoms of Seasonal Allergic Rhinitis in Adults and Pediatric Patients 12 Years of Age and Older’.
The above information is a part of company’s filings submitted to BSE.